ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: All these data demonstrate that any kind of therapy, either cytoreductive or target therapy as TKIs, administered before or after a confirmed diagnosis of CML might change the kinetics of the BCR::ABL1 transcript.